|

enfortumab vedotin Clinical Trials

30 actively recruiting trials across 18 locations

Also known as: AGS 22ME, AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE +8 more

Pipeline

Phase 1: 2Phase 2: 19Phase 4: 2Phase 1/2: 4Phase 2/3: 1

Top Sponsors

  • Memorial Sloan Kettering Cancer Center3
  • Mayo Clinic3
  • National Cancer Institute (NCI)2
  • Fox Chase Cancer Center2
  • Emory University2

Indications

  • Cancer30
  • Metastatic Urothelial Carcinoma5
  • Urothelial Carcinoma4
  • Bladder Cancer3
  • Metastatic Renal Pelvis and Ureter Urothelial Carcinoma2

Other6 trials

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Phase 2
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
Phase 2
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2

Tucson, Arizona2 trials

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

University of Arizona - Cancer Center

Phase 1
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

Duarte, California2 trials

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

City of Hope

Phase 2
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

City of Hope Comprehensive Cancer Center

Phase 2

Atlanta, Georgia2 trials

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Emory University Hospital/Winship Cancer Institute

Phase 1
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Grady Health System

Phase 2

Rochester, Minnesota2 trials

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic in Rochester

Phase 4
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Mayo Clinic in Rochester

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Philadelphia, Pennsylvania2 trials

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Fox Chase Cancer Center - Philadelphia

Phase 2
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Fox Chase Cancer Center - Philadelphia

Phase 2

Phoenix, Arizona1 trial

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Mayo Clinic Hospital in Arizona

Phase 2

Los Angeles, California1 trial

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

San Francisco, California1 trial

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

University of California, San Francisco

Phase 1/2

Santa Monica, California1 trial

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Sarcoma Oncology Center

Phase 2/3

Washington D.C., District of Columbia1 trial

Renal Retention in High Grade Upper Tract Urothelial Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2

Miami, Florida1 trial

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Baptist Alliance MCI

Phase 2

Tampa, Florida1 trial

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Moffitt Cancer Center

Phase 2

Bethesda, Maryland1 trial

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

National Institutes of Health Clinical Center

Phase 2

Ann Arbor, Michigan1 trial

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

University of Michigan Comprehensive Cancer Center

Phase 2

Hackensack, New Jersey1 trial

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

John Theurer Cancer Center at Hackensack University Medical Center

Phase 1/2

Dallas, Texas1 trial

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

UT Southwestern Medical Center

Phase 1/2

Houston, Texas1 trial

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.